Lithium, a potential protective drug in Alzheimer's disease.Neurodegener Dis. 2008; 5(3-4):247-9.ND
Abstract
Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. The main component of these tangles is the cytoskeletal protein tau in hyperphosphorylated form. Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like lithium, could be a potential therapy in Alzheimer's disease. In this short article, we have done a review on tau phosphorylation in Alzheimer's disease and other tauopathies, and on the inhibition of kinases like GSK-3, involved in tau modification.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
18322403
Citation
Engel, T, et al. "Lithium, a Potential Protective Drug in Alzheimer's Disease." Neuro-degenerative Diseases, vol. 5, no. 3-4, 2008, pp. 247-9.
Engel T, Goñi-Oliver P, Gómez de Barreda E, et al. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis. 2008;5(3-4):247-9.
Engel, T., Goñi-Oliver, P., Gómez de Barreda, E., Lucas, J. J., Hernández, F., & Avila, J. (2008). Lithium, a potential protective drug in Alzheimer's disease. Neuro-degenerative Diseases, 5(3-4), 247-9. https://doi.org/10.1159/000113715
Engel T, et al. Lithium, a Potential Protective Drug in Alzheimer's Disease. Neurodegener Dis. 2008;5(3-4):247-9. PubMed PMID: 18322403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Lithium, a potential protective drug in Alzheimer's disease.
AU - Engel,T,
AU - Goñi-Oliver,P,
AU - Gómez de Barreda,E,
AU - Lucas,J J,
AU - Hernández,F,
AU - Avila,J,
Y1 - 2008/03/06/
PY - 2008/3/7/pubmed
PY - 2008/5/16/medline
PY - 2008/3/7/entrez
SP - 247
EP - 9
JF - Neuro-degenerative diseases
JO - Neurodegener Dis
VL - 5
IS - 3-4
N2 - Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. The main component of these tangles is the cytoskeletal protein tau in hyperphosphorylated form. Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like lithium, could be a potential therapy in Alzheimer's disease. In this short article, we have done a review on tau phosphorylation in Alzheimer's disease and other tauopathies, and on the inhibition of kinases like GSK-3, involved in tau modification.
SN - 1660-2862
UR - https://www.unboundmedicine.com/medline/citation/18322403/Lithium_a_potential_protective_drug_in_Alzheimer's_disease_
DB - PRIME
DP - Unbound Medicine
ER -